Imaging's Role in Screening for Fibrosis in MASLD

MASLD affects 40% of the global population. Professional guidelines recommend screening high-risk adults with blood tests first, then noninvasive imaging to detect clinically significant fibrosis and guide management.

• Clinically significant fibrosis (stage F2 or higher) in MASLD is associated with poorer prognosis and guides management decisions, including pharmacotherapy and surveillance.
• Screening targets high-risk adults with diabetes, other cardiometabolic factors, or incidentally detected steatosis.
• Imaging serves as a second-line test to verify and stratify fibrosis risk after initial blood-based tests.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.